Organizers claimed that nearly 2 million Hong Kong protesters took to the streets Sunday in a rally to demand the city's top official resign a day after she suspended — but...China Politicsread more
Heavy rains caused unprecedented delays in planting this year and contributed to record floods across the central United States.Agricultureread more
Stocks in Asia traded mixed on Monday as investors await a U.S. Federal Reserve meeting set to happen later in the week stateside.Asia Marketsread more
Although Cook did not mention companies by name, his commencement speech in Silicon Valley's backyard mentioned data breaches, privacy violations, and even made reference to...Technologyread more
In the survey, 66% of Democratic primary voters say they'd be enthusiastic or comfortable about Biden as their nominee to take on President Trump in the 2020 election. Just...Politicsread more
U.S. ambassador to Israel David Friedman called the gesture a "birthday present" to Trump, who turned 73 on Friday.Politicsread more
The outlook for Germany's economy and political stability are more uncertain than ever, writes Michael Ivanovitch.World Economyread more
Hong Kong democracy activist Joshua Wong walked free from prison on Monday after serving nearly five weeks for contempt of court, pledging to join a mass protest movement...China Politicsread more
The agreement, which is on the framework for the plan of adjustment, provide for more than a 60% average haircut for all $35 billion, a 36% haircut on pre-2012 general...Bondsread more
Target's registers were down on Saturday for several hours preventing customers from checking out.Retailread more
The newspaper wrote that Goldman's executive are hoping CEO David Solomon's changes to a firm that historically thrived in investment banking and trading will boost its...US Marketsread more
Amarin CEO John Thero shrugged off the stock's decline on Monday, telling CNBC that any investor concerned about its latest clinical trial should take a better look at the data.
Shares of the biopharmaceutical company closed down 5.84 percent on Monday after hovering down roughly 7 percent much of the day.
"I think as people begin to understand our data better, they will appreciate that this drug does much more than lipid modification," Thero said on "Power Lunch."
Amarin shares finished the day at $19.82 after researchers began comparing the full study of the clinical trial for its fish oil capsule, Vascepa, released over the weekend, to September's preliminary results.
The stock surged 300 percent after those early results, which showed the drug could reduce cardiovascular events by 25 percent. Shares of Amarin hit a high of $23.34 last Tuesday and are up more than 380 percent year to date.
But researchers are concerned about whether mineral oil, which was given to the placebo group, negatively affected the placebo group's results, making the treatment group's data appear better.
Thero defended the results, saying the mineral oil was reviewed and approved by the Food and Drug Administration prior to the study.
"We believe in our data," he said. "We've presented our data at American Heart Association. It's important to have data subject to scientific debate."
Thero also leaned on a peer review by the New England Journal of Medicine. The journal concluded that the mineral oil "couldn't have explained this significant result," Thero said.
"We stand behind the results and the published results in the New England Journal of Medicine and believe that this is a therapy which is well positioned to help millions of people," he said.
Amarin is now working on its plan to grow its sales force by 250 and focus on operational execution, Thero said.
"I think that our execution will be recognized by the marketplace," he said.
— CNBC's Meg Tirrell contributed to this report.